Lasa Supergeneri

- The company has repaid most of its working capital debt and is currently virtually debt-free. - Remaining debt with Bank of Baroda is under settlement with a verbal nod received for repayment. - No mention of new debt fundraising in the current quarter. - Free cash flow generated will primarily be used for: - Incremental working capital requirements. - Expansion of business (volume growth of existing products). - No discussion or announcement of any current or future equity fundraising. - Management is focused on improving cash flow, return on capital, and utilizing surplus cash for business growth or shareholder rewards (e.g., dividends). - Any additional capacity expansion plans will be internally funded via surplus cash flow. In summary, no explicit plans for new debt or equity fundraising were disclosed; the company prefers leveraging internal accruals to fund growth and working capital needs.

- LASA Supergenerics is currently undergoing a capital expenditure (CAPEX) primarily focused on expanding capacity and volume growth of existing products. - No new products are planned under the current CAPEX; the focus is on volume growth of existing product lines. - The first phase of capacity expansion (adding around 1,000 metric tons to existing 4,300 metric tons, totaling 5,300 metric tons) is expected to complete by March 2021. - Plans for the second phase of capacity expansion (up to 5,800 metric tons) are under evaluation; timelines will be communicated in due course, expected within the next year. - CAPEX done in recent months is yet to be fully capitalized and will reflect once commissioning is complete. - Free cash flows generated will be used for working capital and business expansion. - The company is debt-free except for a balance under settlement and has reserved funds to clear it. - No explicit mention of strategic investments or acquisitions at this time, though Harishree Aromatics scheme is awaiting NCLT approval.

- LASA Supergenerics expects a growth rate of around 7% to 10% if market conditions remain stable (Page 7). - Focus is on volume growth rather than immediate topline jump, especially through existing products (Page 6). - Progesterone (human API) sales are currently small (~Rs. 10 crore included in topline) but expected to pick up gradually (Page 4). - Capacity expansion underway: first phase increasing capacity from 4300 to 5300 metric tons by March, second phase planned within next year (Page 9). - Exports constitute around 50% (direct ~17%), and the company aims to maintain or slightly increase export share (Page 8). - Company emphasizes sustainable EBITDA margins between 20-23% despite competition, aiming to protect profitability amid market uncertainties (Page 11).

- LASA Supergenerics expects a steady growth rate of around 7% to 10% going forward, contingent on favorable market conditions. - The company emphasizes maintaining healthy EBITDA margins around 20-23%, considering the Chinese competition and raw material costs. - EBITDA margins beyond 23-25% are considered unlikely due to competitive pressures. - Growth will mainly be driven by volume expansion of existing products rather than addition of new products. - The human API segment (specifically Progesterone) is expected to grow gradually but is currently a small part of revenue (~Rs. 10 crore included in current topline). - They aim for consistent topline with focus on profitability rather than just sales growth. - Cash flows generated will be reinvested for working capital, capacity expansion, and potentially shareholder rewards like dividends. - The company is virtually debt-free, supporting financial stability for future growth.

The transcript does not explicitly mention the current or expected order book or pending orders for LASA Supergenerics Limited. However, relevant inferences from the Q&A include: - Exports contribute about 17% directly and around 50% including indirect exports, indicating ongoing orders from international markets. - Competition, especially from China, affects order wins due to their inventory and pricing strategies. - The company strives for consistent topline growth despite market challenges. - The bird flu and COVID-19 vaccine drive may impact demand and government tenders, indicating some uncertainty in order inflow. - Litigation and patent protection efforts are ongoing to protect the company's market share. - Capacity expansions (from 4300 to 5300 MT, with plans for 5800 MT) suggest anticipation of increased order volumes. No specific orderbook value or pending orders were disclosed.